文献速递冠心病心力衰竭与心肌病

心肌梗死后室间隔缺损:英国国家注册研究中经皮与外科修补的比较

Post-infarction ventricular septal defect: percutaneous or surgical management in the UK national registry.
PubMed 文献 · Eur Heart J · 2022-01-01

两组长期死亡率无差异(61.1% vs 53.7%,P=0.17),但外科组院内死亡率更低(55.0% vs 44.2%,P=0.048)。心源性休克、经皮路径及冠脉病变血管数是长期死亡的独立相关因素。

要点

  • 外科与经皮修补均为PIVSD可行治疗选择,长期死亡率无显著差异。
  • 外科组院内死亡率低于经皮组,但出院后死亡率无差异。
  • 心源性休克、经皮路径及冠脉病变血管数与长期死亡独立相关。

核心结论

  • 外科与经皮修补均为PIVSD的可行治疗选择。
  • 两组出院后长期死亡率无差异,但外科组院内死亡率更低。

研究设计与样本

  • 按初始治疗方式分组,主要结局为长期死亡率。

主要发现

  • 经皮组16.1%后续接受外科,外科组7.8%后续接受经皮。
  • 从AMI至治疗时间两组相似[经皮9(6-14)天 vs 外科9(4-22)天,P=0.18]。
  • 外科组心源性休克比例更高(62.8% vs 51.9%,P=0.044)。
  • 经皮组年龄更大[72(64-77)岁 vs 67(61-73)岁,P<0.001]且更常经心脏团队讨论。
  • 长期死亡率无差异(61.1% vs 53.7%,P=0.17);院内死亡率外科组更低(55.0% vs 44.2%,P=0.048),出院后死亡率无差异(P=0.65)。

临床怎么用

  • PIVSD患者可根据个体情况选择外科或经皮修补,需心脏团队评估。
  • 合并心源性休克、多支冠脉病变者长期死亡风险更高,应加强管理。

局限性

  • 回顾性观察性设计,存在选择偏倚。
  • 经皮组年龄更大且更常经心脏团队讨论,可能影响组间比较。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: Post-infarction ventricular septal defect (PIVSD) is a mechanical complication of acute myocardial infarction (AMI) with a poor prognosis. Surgical repair is the mainstay of treatment, although percutaneous closure is increasingly undertaken. METHODS AND RESUTS: Patients treated with surgical or percutaneous repair of PIVSD (2010-2021) were identified at 16 UK centres. Case note review was undertaken. The primary outcome was long-term mortality. Patient groups were allocated based upon initial management (percutaneous or surgical). Three-hundred sixty-two patients received 416 procedures (131 percutaneous, 231 surgery). 16.1% of percutaneous patients subsequently had surgery. 7.8% of surgical patients subsequently had percutaneous treatment. Times from AMI to treatment were similar [percutaneous 9 (6-14) vs. surgical 9 (4-22) days, P = 0.18]. Surgical patients were more likely to have cardiogenic shock (62.8% vs. 51.9%, P = 0.044). Percutaneous patients were substantially older [72 (64-77) vs. 67 (61-73) years, P < 0.001] and more likely to be discussed in a heart team setting. There was no difference in long-term mortality between patients (61.1% vs. 53.7%, P = 0.17). In-hospital mortality was lower in the surgical group (55.0% vs. 44.2%, P = 0.048) with no difference in mortality after hospital discharge (P = 0.65). Cardiogenic shock [adjusted hazard ratio (aHR) 1.97 (95% confidence interval 1.37-2.84), P < 0.001), percutaneous approach [aHR 1.44 (1.01-2.05), P = 0.042], and number of vessels with coronary artery disease [aHR 1.22 (1.01-1.47), P = 0.043] were independently associated with long-term mortality. CONCLUSION: Surgical and percutaneous repair are viable options for management of PIVSD. There was no difference in post-discharge long-term mortality between patients, although in-hospital mortality was lower for surgery.

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. Giblett, Matetic, Jenkins, et al. Post-infarction ventricular septal defect: percutaneous or surgical management in the UK national registry. Eur Heart J. 2022. PMID: 36124729. doi:10.1093/eurheartj/ehac511

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。